Document is current
Any future updates will be listed below
-
Authors
Parlar, Sitki Cem
Senkevich, Konstantin
Yu, Eric
Ruskey, Jennifer A.
Ahmad, Jamil
Asayesh, Farnaz
Spiegelman, Dan
Waters, Cheryl
Monchi, Oury
Dauvilliers, Yves
Dupré, Nicolas
Greenbaum, Lior
Hassin-Baer, Sharon
Miliukhina, Irina
Timofeeva, Alla
Emelyanov, Anton
Pchelina, Sofya
Alcalay, Roy N.
Fon, Edward A.
Trempe, Jean-François
Gan-Or, Ziv
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research
Fonds de Recherche du Québec - Santé
- License Information
-
More Information
Article History
Received: 13 October 2024
Accepted: 2 April 2025
First Online: 29 April 2025
Competing interests
: Z.G.O. received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Ono Therapeutics, Denali, Handl Therapeutics, Neuron23, Bial Biotech, Bial, UCB, Capsida, Vanqua Bio, Congruence Therapeutics, Takeda, Jazz Pharmaceuticals, Guidepoint, Lighthouse, and Deerfield.
